Nature Reviews Clinical Oncology

Article	Citations
Broadening horizons: the role of ferroptosis in cancer	1609
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	1037
Immunotherapies for hepatocellular carcinoma	914
PD-L1 as a biomarker of response to immune-checkpoint inhibitors	838
Liquid biopsy enters the clinic — implementation issues and future challenges	736
Unlocking the potential of antibody–drug conjugates for cancer therapy	625
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	609
The emerging roles of circRNAs in cancer and oncology	608
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	596
Clinical and therapeutic relevance of cancer-associated fibroblasts	590
Immune-checkpoint inhibitors: long-term implications of toxicity	514
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	461
Harnessing cytokines and chemokines for cancer therapy	446
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	446
Advancing therapy for osteosarcoma	438
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	405
Long-term outcomes following CAR T cell therapy: what we know so far	394
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	389
Clinical relevance of tumour-associated macrophages	368
Targeting drugs to tumours using cell membrane-coated nanoparticles	355
Clinical implications of T cell exhaustion for cancer immunotherapy	351
Rising incidence of early-onset colorectal cancer — a call to action	348
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	331
The global burden of lung cancer: current status and future trends	314
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	306

Understanding and overcoming resistance to PARP inhibitors in cancer therapy	287
Senescence and cancer — role and therapeutic opportunities	284
Intratumoural administration and tumour tissue targeting of cancer immunotherapies	281
Nasopharyngeal carcinoma: an evolving paradigm	277
Therapeutic targeting of the hypoxic tumour microenvironment	254
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	240
Protein degraders enter the clinic — a new approach to cancer therapy	232
The current state of the art and future trends in RAS-targeted cancer therapies	231
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma	215
Is early-onset cancer an emerging global epidemic? Current evidence and future implications	215
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	210
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	209
The implications of IDH mutations for cancer development and therapy	204
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	200
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention	200
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer	199
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	198
The emerging role of photoacoustic imaging in clinical oncology	195
Therapy with oncolytic viruses: progress and challenges	192
Fundamentals and developments in fluorescence-guided cancer surgery	178
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC	174
Towards precision medicine for AML	167
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy	167
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	166
Gut microbiota in colorectal cancer development and therapy	165
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy	164
Advancing therapy for neuroblastoma	162
Tumour burden and efficacy of immune-checkpoint inhibitors	160
Immunogenicity of CAR T cells in cancer therapy	158
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	156
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	153
The emerging roles of γδ T cells in cancer immunotherapy	149
The blood–tumour barrier in cancer biology and therapy	149
The nuclear export protein XPO1 — from biology to targeted therapy	145
Radiotheranostics in oncology: current challenges and emerging opportunities	143
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours	140
Circulating tumour DNA — looking beyond the blood	138
Neoadjuvant therapy for pancreatic cancer	138
Towards clinical translation of FLASH radiotherapy	134
Precision oncology in metastatic colorectal cancer — from biology to medicine	129
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer	116
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	116
Novel approaches to target the microenvironment of bone metastasis	113
The roles and implications of RNA m6A modification in cancer	112
Emerging evidence for adapting radiotherapy to immunotherapy	112
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	110
Thermal immuno-nanomedicine in cancer	110
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn	103
Humanized mouse models for immuno-oncology research	100
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	100

The multiple roles of LDH in cancer	100
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice	99
Advances in the clinical management of uveal melanoma	93
Circulating tumour cells for early detection of clinically relevant cancer	88
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management	87
Criteria for the translation of radiomics into clinically useful tests	86
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects	84
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide	78
Exploring the next generation of antibody–drug conjugates	77
Integrated MRI-guided radiotherapy — opportunities and challenges	76
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy	74
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine	72
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	70
Predicting tumour radiosensitivity to deliver precision radiotherapy	66
Beneficial autoimmunity improves cancer prognosis	66
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	63
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy	62
The immune landscape of common CNS malignancies: implications for immunotherapy	60
Mitigating acute chemotherapy-associated adverse events in patients with cancer	60
Towards precision oncology with patient-derived xenografts	60
Harnessing big data to characterize immune-related adverse events	57
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	56
Cholangiocarcinoma — novel biological insights and therapeutic strategies	56
New treatment strategies for advanced-stage gastrointestinal stromal tumours	56
Biomarkers for immunotherapy of hepatocellular carcinoma	55
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	54
Systemic therapy for early-stage breast cancer: learning from the past to build the future	50
Advancing CAR T cell therapy through the use of multidimensional omics data	50
Myeloid-derived suppressor cells in cancer and cancer therapy	46
The oligometastatic spectrum in the era of improved detection and modern systemic therapy	45
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma	43
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells	41
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	40
Rare molecular subtypes of lung cancer	39
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	39
Barriers in access to oncology drugs — a global crisis	39
Global epidemiology of epithelial ovarian cancer	38
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment	38
The clinical development of antibody–drug conjugates — lessons from leukaemia	37
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer	36
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	35
Advances in the management of peritoneal malignancies	35
Heterogeneity and treatment landscape of ovarian carcinoma	34
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	33
Molecular tumour boards — current and future considerations for precision oncology	33
Immunotherapy approaches for malignant pleural mesothelioma	32
Lung cancer in patients who have never smoked — an emerging disease	31
Improving outcomes in patients with oesophageal cancer	28
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors	27
Drug-tolerant persister cells in cancer: the cutting edges and future directions	27
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	26
Dendritic cells as orchestrators of anticancer immunity and immunotherapy	25
Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century	24
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions	24
Advancing oncolytic virus therapy by understanding the biology	24
Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?	24
TAM family kinases as therapeutic targets at the interface of cancer and immunity	24
Targeting cuproplasia and cuproptosis in cancer	23
NIR-II light in clinical oncology: opportunities and challenges	23
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	22
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives	21
Tumour antigen-induced T cell exhaustion — the archenemy of immune-hot malignancies	21
The ten genes for breast (and ovarian) cancer susceptibility	21
BRAF — a tumour-agnostic drug target with lineage-specific dependencies	21
PARP inhibitors coming of age	19
The value of anticancer drugs — a regulatory view	19
Computational immunogenomic approaches to predict response to cancer immunotherapies	19
Current understanding and management of CAR T cell-associated toxicities	19
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain	17
Personalizing adjuvant therapy for patients with colorectal cancer	17
Early stage gastric adenocarcinoma: clinical and molecular landscapes	17
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies	17
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	17
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine	17
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed	16
Pharmacological reactivation of p53 in the era of precision anticancer medicine	16
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination	16
An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?	16
Immunotherapy biomarkers: the long and winding road	15
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development	14

GPRC5D as a novel immunotherapeutic target in multiple myeloma	14
Optimal systemic therapy for high-risk resectable melanoma	13
First clinical proof-of-concept that FMT can overcome resistance to ICIs	13
Prospective clinical deployment of machine learning in radiation oncology	13
FOLFOX–HAIC active in large HCC	12
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	12
Intraoperative radiotherapy for breast cancer: powerful evidence to change practice	12
Exploiting bacteria for cancer immunotherapy	12
Tebentafusp for uveal melanoma	11
Cancer mRNA vaccines: clinical advances and future opportunities	11
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma	11
Claudin 18.2 as a novel therapeutic target	11
Pembrolizumab for HER2+ gastric cancer	10
New first-line therapy for dMMR/MSI-H CRC	10
Bispecific and multispecific antibodies in oncology: opportunities and challenges	10
Aumolertinib is effective in NSCLC	10
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy	10
Oncology approvals in 2020: a year of firsts in the midst of a pandemic	9
Translating noninvasive molecular responses into clinical reality for cancer immunotherapy	9
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe	9
Newly approved cancer drugs in China — innovation and clinical benefit	9
Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond	8
Risk-based oral cancer screening — lessons to be learnt	8
Belzutifan has potential in RCC	8
Dissecting the immunogenomic biology of cancer for biomarker development	8
Cemiplimab is a new option in BCC	7
Exploring a new pathway for biomarker-based approval of immunotherapies	7
Targeting ATR in patients with cancer	7
TNT and local recurrence in the RAPIDO trial — untangling the puzzle	7
Progress in systemic therapy for advanced-stage urothelial carcinoma	7
Author Correction: Clinical relevance of tumour-associated macrophages	7
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	7
Uncovering adagrasib resistance	7
Reply to ‘Intraoperative radiotherapy for breast cancer: powerful evidence to change practice’	7
Is representation enough or should we be targeting equitable inclusion?	7
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19	7
The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?	6
LAG3 inhibition improves outcomes	6
Gut microbes as biomarkers of ICI response — sharpening the focus	6
Overall survival as a primary end point in multiple myeloma trials	6
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	6
Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma	6
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	6
PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching	5
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer	5
Risk-adjusting away volume as a quality metric for surgical oncology: a perspective worth re-visiting	5
FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer	5
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	5
Problematic crossovers in cancer drug trials	5
Camrelizumab efficacious in NPC	4
Lorlatinib CROWNed	4
Should the control arms of randomized trials have an expiry date?	4
HAIC-FO improves outcomes in HCC	4
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions	4
Telemedicine as patient-centred oncology care: will we embrace or resist disruption?	4
Dabrafenib–trametinib moves to the first line in low-grade glioma	4
Copanlisib safe and active in combination	4
Optimizing the FDA’s Project Optimus: opportunities and challenges	4
Role of neoadjuvant chemoimmunotherapy for resectable NSCLC	4
Determinants of response and resistance to T cell-engaging therapies in multiple myeloma	4
Adjuvant olaparib — should all patients with breast cancer have genetic testing?	4
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis	4
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	4
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	4
A new standard for mastocytosis	3
CDK4/6 inhibitors for HR+HER2− early stage breast cancer — when to escalate treatment?	3
Precision oncology for KRASG12C-mutant colorectal cancer	3
T-DXd active in HER2-low disease	3
Engaging results with glofitamab	3
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	3
Belzutifan is active in VHL-related cancers	3
Finding the Goldilocks zone in neoadjuvant radioimmunotherapy	3
Improving outcomes demands patient-centred interventions and equitable delivery	3
Benefit with cemiplimab in cervical cancer	3
Allogeneic CAR T cells show promise	3
Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE	3
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	3
Dabrafenib–trametinib is effective in paediatric high-grade glioma	3
Novel ICI–TKI combination improves HCC outcomes	3
KEYNOTE-355 — OS benefit now reported	3
Sotorasib effective in KRAS-mutant NSCLC	3
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	3
Defining clinically important overall survival thresholds: lessons from quality of life	3
KTE-X19 efficacious in adults with B-ALL	3
Newly diagnosed AML: quizartinib improves OS	3
Medulloblastoma: prognostic subtypes revealed	3
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders	3
HPV-associated oropharyngeal cancer — discussion points	2
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	2
Nucleic acid-based drugs for patients with solid tumours	2
Whole-genome sequencing for myeloid disease: one assay to stratify them all?	2
Pembrolizumab tunes up chemotherapy in cervical cancer	2
Capivasertib delays disease progression	2
Pembrolizumab can delay progression of TNBC	2
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	2